Nanomedicine-Mediated Drug Delivery for Potential Treatment of Inflammatory Bowel Disease: A Narrative Review

References

• Hazel K , O’Connor A . Emerging treatments for inflammatory bowel disease. Ther. Adv. Chronic. Dis. 11, 2040622319899297 (2020).
   Web of Science ®Google Scholar
• Haneishi Y , Furuya Y , Hasegawa M , Picarelli A , Rossi M , Miyamoto J . Inflammatory bowel diseases and gut microbiota. Int. J. Mol. Sci. 24(4), 3817 (2023).
   PubMed Web of Science ®Google Scholar
• Zhang M , Wang X , Han MK , Collins JF , Merlin D . Oral administration of ginger-derived nanolipids loaded with siRNA as a novel approach for efficient siRNA drug delivery to treat ulcerative colitis. Nanomedicine 12(16), 1927–1943 (2017).
   PubMed Web of Science ®Google Scholar
• Cai Z , Wang S , Li J . Treatment of inflammatory bowel disease: a comprehensive review. Front. Med. 8, 765474 (2021).
   Web of Science ®Google Scholar
• Kaplan GG . The global burden of IBD: from 2015 to 2025. Nat. Rev. Gastroenterol. Hepatol. 12(12), 720–727 (2015).
   PubMed Web of Science ®Google Scholar
• Du L , Ha C . Epidemiology and pathogenesis of ulcerative colitis. Gastroenterol. Clin. North Am. 49(4), 643–654 (2020).
   PubMed Web of Science ®Google Scholar
• Nguyen ALH , Sparrow MP . Evolving role of thiopurines in inflammatory bowel disease in the era of biologics and new small molecules. Dig. Dis. Sci. 66(10), 3250–3262 (2021).
   PubMed Web of Science ®Google Scholar
• Herfarth HH , Kappelman MD , Long MD , Isaacs KL . Use of methotrexate in the treatment of inflammatory bowel diseases. Inflamm. Bowel Dis. 22(1), 224–233 (2016).
   PubMed Web of Science ®Google Scholar
• Anjie SI , Hulshoff MS , D’Haens G . Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand? Expert Opin. Biol. Ther. 23(4), 341–351 (2023).
   PubMed Web of Science ®Google Scholar
• Ben-Horin S , Kopylov U , Chowers Y . Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun. Rev. 13(1), 24–30 (2014).
   PubMed Web of Science ®Google Scholar
• Jensen KJ , Jensen CB , Wennerström C , Burisch J , Petersen J . Drug utilization of biologic therapy in Crohn’s disease and ulcerative colitis: a population-based Danish cohort study 2015–2020. Scand. J. Gastroenterol. 58(7), 726–736 (2023).
   PubMed Web of Science ®Google Scholar
• Liu W , Dong Z , Liu K et al. Targeting strategies of oral nano-delivery systems for treating inflammatory bowel disease. Int. J. Pharm. 600, 120461 (2021).
   PubMedGoogle Scholar
• Yang C , Merlin D . Nanoparticle-mediated drug delivery systems for the treatment of IBD: current perspectives. Int. J. Nanomed. 14, 8875–8889 (2019).
   PubMed Web of Science ®Google Scholar
• Beloqui A , Coco R , Alhouayek M et al. Budesonide-loaded nanostructured lipid carriers reduce inflammation in murine DSS-induced colitis. Int. J. Pharm. 454(2), 775–783 (2013).
   PubMedGoogle Scholar
• Shrestha N , Xu Y , Prévost JRC et al. Impact of PEGylation on an antibody-loaded nanoparticle-based drug delivery system for the treatment of inflammatory bowel disease. Acta Biomater. 140, 561–572 (2022).
   PubMed Web of Science ®Google Scholar
• Ahamad N , Kar A , Mehta S et al. Immunomodulatory nanosystems for treating inflammatory diseases. Biomaterials 274, 120875 (2021).
   PubMed Web of Science ®Google Scholar
• Li S , Zhang F , Zhang Q . Pathological features-based targeted delivery strategies in IBD therapy: a mini review. Biomed. Pharmacother. 151, 113079 (2022).
   PubMed Web of Science ®Google Scholar
• Dutta P , Mukherjee K , Saha A , Das A , Badwaik HR , Giri TK . Colonic delivery of surface charge decorated nanocarrier for IBD therapy. J. Drug Deliv. Sci. Technol. 76, 103754 (2022).
   Google Scholar
• Yuba E . Development of functional liposomes by modification of stimuli-responsive materials and their biomedical applications. J. Mater. Chem. B 8(6), 1093–1107 (2020).
   PubMed Web of Science ®Google Scholar
• Makhlof A , Tozuka Y , Takeuchi H . pH-sensitive nanospheres for colon-specific drug delivery in experimentally induced colitis rat model. Eur. J. Pharm. Biopharm. 72(1), 1–8 (2009).
   PubMed Web of Science ®Google Scholar
• Khanna R , Ma C , Jairath V , Vande Casteele N , Zou G , Feagan BG . Endoscopic assessment of inflammatory bowel disease activity in clinical trials. Clin. Gastroenterol. Hepatol. 20(4), 727–736 (2022).
   PubMed Web of Science ®Google Scholar
• Barani M , Rahdar A , Sargazi S , Amiri MS , Sharma PK , Bhalla N . Nanotechnology for inflammatory bowel disease management: detection, imaging and treatment. Sens. Bio-Sens. Res. 32, 100417 (2021).
   Google Scholar
• Wu Y , Briley K , Tao X . Nanoparticle-based imaging of inflammatory bowel disease. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 8(2), 300–315 (2016).
   PubMed Web of Science ®Google Scholar
• Wu Y , Briley-Saebo K , Xie J et al. Inflammatory bowel disease: MR- and SPECT/CT-based macrophage imaging for monitoring and evaluating disease activity in experimental mouse model–pilot study. Radiology 271(2), 400–407 (2014).
   PubMed Web of Science ®Google Scholar
• Naha PC , Hsu JC , Kim J et al. Dextran-coated cerium oxide nanoparticles: a computed tomography contrast agent for imaging the gastrointestinal tract and inflammatory bowel disease. ACS Nano 14(8), 10187–10197 (2020).
   PubMed Web of Science ®Google Scholar
• Laroui H , Theiss AL , Yan Y et al. Functional TNF-α gene silencing mediated by polyethyleneimine/TNF-α siRNA nanocomplexes in inflamed colon. Biomaterials 32(4), 1218–1228 (2011).
   PubMed Web of Science ®Google Scholar
• Xiao B , Laroui H , Ayyadurai S et al. Mannosylated bioreducible nanoparticle-mediated macrophage-specific TNF-α RNA interference for IBD therapy. Biomaterials 34(30), 7471–7482 (2013).
   PubMed Web of Science ®Google Scholar
• Xiao B , Laroui H , Viennois E et al. Nanoparticles with surface antibody against CD98 and carrying CD98 small interfering RNA reduce colitis in mice. Gastroenterology 146(5), 1289–1300 (2014).
   PubMed Web of Science ®Google Scholar
• Liu J , Ren H , Zhang C et al. Orally-delivered, cytokine-engineered extracellular vesicles for targeted treatment of inflammatory bowel disease. Small 2023, e2304023 (2023).
   Google Scholar
• Özcan A , Sahin D , Impellizzieri D et al. Nanoparticle-coupled topical methotrexate can normalize immune responses and induce tissue remodeling in psoriasis. J. Invest. Dermatol. 140(5), 1003–1014 (2020).
   PubMed Web of Science ®Google Scholar
• Ghosh S , Ghosh S , Sil PC . Role of nanostructures in improvising oral medicine. Toxicol. Rep. 6, 358–368 (2019).
   PubMed Web of Science ®Google Scholar
• Chen H , Wang L , Zeng X et al. Exosomes, a new star for targeted delivery. Front. Cell Dev. Biol. 9, 751079 (2021).
   PubMed Web of Science ®Google Scholar
• Kalluri R , LeBleu VS . The biology, function, and biomedical applications of exosomes. Science 367(6478), eaau6977 (2020).
   PubMed Web of Science ®Google Scholar
• Jiang L , Shen Y , Guo D et al. EpCAM-dependent extracellular vesicles from intestinal epithelial cells maintain intestinal tract immune balance. Nat. Commun. 7, 13045 (2016).
   PubMed Web of Science ®Google Scholar
• Yang X , Meng S , Jiang H , Chen T , Wu W . Exosomes derived from interleukin-10-treated dendritic cells can inhibit trinitrobenzene sulfonic acid-induced rat colitis. Scand. J. Gastroenterol. 45(10), 1168–1177 (2010).
   PubMed Web of Science ®Google Scholar
• Yu L , Luo Z , Chen T et al. Bioadhesive nanoparticles for local drug delivery. Int. J. Mol. Sci. 23(4), 2370 (2022).
   PubMed Web of Science ®Google Scholar
• Zhao P , Xia X , Xu X et al. Nanoparticle-assembled bioadhesive coacervate coating with prolonged gastrointestinal retention for inflammatory bowel disease therapy. Nat. Commun. 12, 7162 (2021).
   PubMed Web of Science ®Google Scholar
• Moulari B , Béduneau A , Pellequer Y , Lamprecht A . Lectin-decorated nanoparticles enhance binding to the inflamed tissue in experimental colitis. J. Control. Rel. 188, 9–17 (2014).
   PubMed Web of Science ®Google Scholar
• Dianzani C , Foglietta F , Ferrara B et al. Solid lipid nanoparticles delivering anti-inflammatory drugs to treat inflammatory bowel disease: effects in an in vivo model. World J. Gastroenterol. 23(23), 4200–4210 (2017).
   PubMed Web of Science ®Google Scholar
• Jhundoo HD , Siefen T , Liang A et al. Anti-inflammatory activity of chitosan and 5-amino salicylic acid combinations in experimental colitis. Pharmaceutics 12(11), 1038 (2020).
   PubMed Web of Science ®Google Scholar
• Mohan LJ , Daly JS , Ryan BM , Ramtoola Z . Oral infliximab nanomedicines for targeted treatment of inflammatory bowel diseases. Eur. J. Pharm. Sci. 183, 106379 (2023).
   PubMed Web of Science ®Google Scholar
• Melero A , Draheim C , Hansen S et al. Targeted delivery of cyclosporine A by polymeric nanocarriers improves the therapy of inflammatory bowel disease in a relevant mouse model. Eur. J. Pharm. Biopharm. 119, 361–371 (2017).
   PubMed Web of Science ®Google Scholar
• Shinn J , Lee J , Lee SA et al. Oral nanomedicines for siRNA delivery to treat inflammatory bowel disease. Pharmaceutics 14(9), 1969 (2022).
   PubMed Web of Science ®Google Scholar
• Aouadi M , Tesz GJ , Nicoloro SM et al. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature 458(7242), 1180–1184 (2009).
   PubMed Web of Science ®Google Scholar
• Mohan LJ , Daly JS , Ryan BM , Ramtoola Z . The future of nanomedicine in optimising the treatment of inflammatory bowel disease. Scand. J. Gastroenterol. 54(1), 18–26 (2019).
   PubMed Web of Science ®Google Scholar
• Huang Z , Gan J , Jia L et al. An orally administrated nucleotide-delivery vehicle targeting colonic macrophages for the treatment of inflammatory bowel disease. Biomaterials 48, 26–36 (2015).
   PubMed Web of Science ®Google Scholar
• Senhaji N , Kojok K , Darif Y , Fadainia C , Zaid Y . The contribution of CD40/CD40L axis in inflammatory bowel disease: an update. Front. Immunol. 6, 529 (2015).
   PubMed Web of Science ®Google Scholar
• Arranz A , Reinsch C , Papadakis KA et al. Treatment of experimental murine colitis with CD40 antisense oligonucleotides delivered in amphoteric liposomes. J. Control. Rel. 165(3), 163–172 (2013).
   PubMed Web of Science ®Google Scholar
• Chassaing B , Aitken JD , Malleshappa M , Vijay-Kumar M . Dextran sulfate sodium (DSS)-induced colitis in mice. Curr. Protoc. Immunol. 104, Unit-15.25 (2014).
   PubMedGoogle Scholar
• Solomon L , Mansor S , Mallon P et al. The dextran sulphate sodium (DSS) model of colitis: an overview. Comp. Clin. Pathol. 19, 235–239 (2010).
   Google Scholar
• Antoniou E , Margonis GA , Angelou A et al. The TNBS-induced colitis animal model: an overview. Ann. Med. Surg. 11, 9–15 (2016).
   PubMed Web of Science ®Google Scholar
• Vafaei SY , Abdolghaffari AH , Mahjub R et al. Budesonide-loaded hyaluronic acid nanoparticles for targeted delivery to the inflamed intestinal mucosa in a rodent model of colitis. Bio. Med. Res. Int. 2022, 7776092 (2022).
   Google Scholar
• Feng Z , Jiao L , Wu Z et al. A novel nanomedicine ameliorates acute inflammatory bowel disease by regulating macrophages and T-cells. Mol. Pharm. 18(9), 3484–3495 (2021).
   PubMedGoogle Scholar
• Laroui H , Dalmasso G , Nguyen HTT , Yan Y , Sitaraman SV , Merlin D . Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology 138(3), 843–853 (2010).
   PubMed Web of Science ®Google Scholar
• Wilson DS , Dalmasso G , Wang L , Sitaraman SV , Merlin D , Murthy N . Orally delivered thioketal-nanoparticles loaded with TNFα-siRNA target inflammation and inhibit gene expression in the intestines. Nat. Mater. 9(11), 923–928 (2010).
   PubMed Web of Science ®Google Scholar
• Lee Y , Sugihara K , Gillilland MG , Jon S , Kamada N , Moon JJ . Hyaluronic acid-bilirubin nanomedicine for targeted modulation of dysregulated intestinal barrier, microbiome and immune responses in colitis. Nat. Mater. 19(1), 118–126 (2020).
   PubMed Web of Science ®Google Scholar
• Lee Y , Kim H , Kang S , Lee J , Park J , Jon S . Bilirubin nanoparticles as a nanomedicine for anti-inflammation therapy. Angew. Chem. Int. Ed. 55(26), 7460–7463 (2016).
   PubMed Web of Science ®Google Scholar
• Rahman AT , Shin J , Whang CH et al. Bilirubin nanomedicine rescues intestinal barrier destruction and restores mucosal immunity in colitis. ACS Nano 17(11), 10996–11013 (2023).
   PubMed Web of Science ®Google Scholar
• Li S , Wu T , Wu J et al. Cyclosporine A-encapsulated pH/ROS dual-responsive nanoformulations for the targeted treatment of colitis in mice. ACS Biomater. Sci. Eng. 9(10), 5737–5746 (2023).
   PubMed Web of Science ®Google Scholar
• Can Demirdöğen B . Potential role of calcifying nanoparticles in the etiology of multiple sclerosis. Med. Hypotheses 128, 25–27 (2019).
   PubMed Web of Science ®Google Scholar
• Moulari B , Pertuit D , Pellequer Y , Lamprecht A . The targeting of surface modified silica nanoparticles to inflamed tissue in experimental colitis. Biomaterials 29(34), 4554–4560 (2008).
   PubMed Web of Science ®Google Scholar
• Wei K , Gong F , Wu J et al. Orally administered silicon hydrogen nanomaterials as target therapy to treat intestinal diseases. ACS Nano (2023). doi:10.1021/acsnano.3c06551
   Web of Science ®Google Scholar
• Zheng JD , He Y , Yu HY et al. Unconjugated bilirubin alleviates experimental ulcerative colitis by regulating intestinal barrier function and immune inflammation. World J. Gastroenterol. 25(15), 1865–1878 (2019).
   PubMed Web of Science ®Google Scholar
• Lea T . Caco-2 cell line. In: The Impact of Food Bioactives on Health: In Vitro and Ex Vivo Models. Verhoeckx K , Cotter P , López-Expósito I et al.et al. ( Eds). Springer (2015). www.ncbi.nlm.nih.gov/books/NBK500149/ (Accessed 6 June 2023 ).
   Google Scholar
• Marotti V , Xu Y , Michalowski CB et al. A nanoparticle platform for combined mucosal healing and immunomodulation in inflammatory bowel disease treatment. Bioact. Mater. 32, 206 (2024).
   PubMed Web of Science ®Google Scholar
• Celani LMS , Egito EST , Azevedo ÍM , Oliveira CN , Dourado D , Medeiros AC . Treatment of colitis by oral negatively charged nanostructured curcumin in rats. Acta Cir. Bras. 37(6), e370602 (2022).
   PubMed Web of Science ®Google Scholar
• Kshirsagar SJ , Bhalekar MR , Patel JN , Mohapatra SK , Shewale NS . Preparation and characterization of nanocapsules for colon-targeted drug delivery system. Pharm. Dev. Technol. 17(5), 607–613 (2012).
   PubMed Web of Science ®Google Scholar
• Jain A , Bhattacharya S . Recent advances in nanomedicine preparative methods and their therapeutic potential for colorectal cancer: a critical review. Front. Oncol. 13, 1211603 (2023).
   PubMed Web of Science ®Google Scholar
• Mertz A , Nguyen NA , Katsanos KH , Kwok RM . Primary sclerosing cholangitis and inflammatory bowel disease comorbidity: an update of the evidence. Ann. Gastroenterol. 32(2), 124–133 (2019).
   PubMed Web of Science ®Google Scholar
• Dyson JK , Beuers U , Jones DEJ , Lohse AW , Hudson M . Primary sclerosing cholangitis. Lancet 391(10139), 2547–2559 (2018).
   PubMed Web of Science ®Google Scholar
• Gao L , Wang L , Woo E et al. Clinical management of primary biliary cholangitis–strategies and evolving trends. Clin. Rev. Allergy Immunol. 59(2), 175–194 (2020).
   PubMed Web of Science ®Google Scholar
• Pearson RM , Podojil JR , Shea LD , King NJC , Miller SD , Getts DR . Overcoming challenges in treating autoimmunity: development of tolerogenic immune-modifying nanoparticles. Nanomed. Nanotechnol. Biol. Med. 18, 282–291 (2019).
   PubMed Web of Science ®Google Scholar
• Chen F , Liu Q , Xiong Y , Xu L . Current strategies and potential prospects of nanomedicine-mediated therapy in inflammatory bowel disease. Int. J. Nanomed. 16, 4225–4237 (2021).
   PubMed Web of Science ®Google Scholar